NCT05411094 2026-03-18
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
11 trialsNCT04005690 2026-02-27
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06545942 2025-12-23
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT04753879 2025-12-04
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05093231 2025-09-18
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Recruiting
NCT05932862 2025-09-05
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Phase 1 Recruiting
NCT06441747 2025-07-29
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT05222971 2025-01-28
OPTIMUM
Asan Medical Center
Phase 2 Recruiting
NCT03991832 2024-07-18
SOLID
University Health Network, Toronto
Phase 2 Recruiting
NCT06078787 2024-05-06
PALBOLA
Azienda Ospedaliero-Universitaria di Modena
Phase 2 Recruiting